Extracorporeal Shock Wave Therapy Device Market 2018 Opportunities, Competition from Opponents, Dynamics, Demand, Challenge and Risk and Forecast to 2023
The Extracorporeal Shock Wave Therapy Device Market report provides
valuable and unique information which is very essential. Further it also covers key players,application and future market condition.This
information is extremely useful information for new and growing
company to mark themself over the market
Extracorporeal Shock Wave Therapy (ESWT) is a noninvasive, FDA-approved
technology that uses shock waves to treat chronic, painful conditions
of the musculoskeletal system. The procedure has also proven to be
extremely effective for improved penile function. ESWT produces intense, short energy waves that travel faster than the speed of sound.
This shock wave, in turn, generates pulses of high pressure sound that travel through the skin, initiating tissue repair. ESWT can often heal even chronic conditions that the body has previously been unable to repair on
its own. The weak shock waves interact with deep tissue where they cause mechanical stress and microtra uma that stimulate the body to jump into action.
Request a Sample of this report from:
Following are the Key Manufacturers:
Chattanooga(DJO)(US), BTL(UK), Storz Medical(Switzerland), EMS Electro Medical Systems(Switzerland), MTS Medical(Germany), Zimmer MedizinSysteme(Germany), Gymna(Belgium), Likamed GmbH(Germany), Inceler Medikal(Turkey), HANIL-TM(Korea), HnT Medical(Korea), Urontech(Korea), Wikkon(China), Longest(China), Xiangyu Medical(China), Shengchang Medical(China)
Extracorporeal Shock Wave Therapy Device Market Overview:
Extracorporeal Shock Wave Therapy Device Market by Type and Application
Extracorporeal Shock Wave Therapy Device Market Size by Type and Application
Potential Application of Extracorporeal Shock Wave Therapy Device in Future
Top Consumer/End Users of Extracorporeal Shock Wave Therapy Device Market Research Report
Extracorporeal Shock Wave Therapy Device Market Competition by Manufacturers Profiles/Analysis
Extracorporeal Shock Wave Therapy Device Market Capacity, Supply (Production), Consumption, Export, Import by Region
Extracorporeal Shock Wave Therapy Device Market Production, Revenue (Value), Price Trend by Type,Application
Industrial Chain, Sourcing Strategy and Downstream Buyers
Marketing Strategy Analysis, Distributors/Traders
Market Effect Factors Analysis
Have Any Query? Ask Our Expert @ :
Extracorporeal Shock Wave Therapy Device Market Forecast 2018-2023
Woodstock, GA, June 09, 2017 – Tissue Regeneration Technologies, LLC (TRT) is pleased to announce that Major League Baseball team, The Cleveland Indians, has officially adopted SoftWaveTM technology via the TRT OrthoGold 100 series ESWT device, exclusively through AcousTek, LLC.
Many of The Indians’ players have benefitted from SoftWaveTM since the team began using the therapeutic technology in February 2017.
SoftWaveTM is a breakthrough patented non-invasive atraumatic treatment technology that activates endogenous musculoskeletal stem cells through proprietary high-energy unfocused electrohydraulically-produced acoustic pulses. It is proving to be the silver bullet in the sports med armamentarium across many sports specialties and in every day lives of people dealing with chronic and acute pain...
Read the entire press release here...
The potential for using low intensity shockwave therapy to treat erectile dysfunction (ED) was first proposed in 2010, and early studies have suggested that it may provide some benefits. However, the ideal energy levels and frequency of treatment are a matter of debate.
Two experts took up that debate during Sunday morning’s Prime Time plenary session in a 20-minute presentation moderated by Ranjith Ramasamy, MD, assistant professor and Director of Reproductive Urology at the University of Miami.
To read the rest of the debate click here
The Global Alliance for Regenerative Medicine, a world-renowned regenerative medicine clinic, announced today that it is now offering unfocused acoustic wave therapy (aka “GARM Wave”) for the treatment of musculoskeletal pain, inflamed and injured tissue, as well as for blood flow improvement. “This technology seems to bring about significant relief of patients’ pain from joint and soft tissue injuries, as well as pain form arthritis or tendonitis/tendonosis. In addition to rapid pain relief, the GARM Wave seems to contribute to reduced injury recovery time,” stated GARM’s Medical Director, Glenn C. Terry, M.D.
Read more here.
Woodstock, GA, April 19, 2016 – Tissue Regeneration Technologies, LLC (TRT) announces an Exclusive License Agreement with Acoustic Wave Cell Therapy, Inc. (AWCT), a Delaware Corporation, whereby AWCT will utilize TRT's extensive patent portfolio to develop and market low energy acoustic wave treatments for multiple internal organs and associated tissues and pathologies.
We have set up a Facebook and Twitter for the TRT community to get the latest updates!